Author:
Li Yong,Cao Fengjun,Li Mingxing,Li Pindong,Yu Yuandong,Xiang Longchao,Xu Tao,Lei Jinhua,Tai Yun Yan,Zhu Jianyong,Yang Bingbing,Jiang Yingpin,Zhang Xiufang,Duo Long,Chen Ping,Yu Xiongjie
Funder
National Natural Science Foundation of China
Hubei Provincial Natural Science Foundation of China
Hubei Province Health and Family Planning Scientific Research Project
Union Hospital Key Laboratory Foundation of Biological Target Therapy
Beijing medical and health foundation
the Scientific Research Foundation for Doctors of Shiyan Renmin Hospital
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Hsu PP, Shaw AT. Lung Cancer: a wily genetic opponent. Cell. 2017;169(5):777–9.
2. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12(9):511–26.
3. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Sacca M, Eramo A, De Maria R. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19(5):768–78.
4. Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, Orkin S, Berns A, van Lohuizen M. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial- mesenchymal transition in non-small-cell lung Cancer. Cancer Cell. 2016;29(1):17–31.
5. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;10(4):350.
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献